Kodiak skyrockets on positive study data for 2 eye drugs
Published . Updated .
The Phase 3 findings suggested Kodiak might have multiple threats to Regeneron’s Eylea and added more than $3 billion to the company’s market value.
Directly affected
- No company is named in this report.
Indirectly affected
- GIEQ GOLDMAN SACHS ETF TR DATA ENHA
GA selected GIEQ as a RELATED security because its canonical security name directly matches this event's themes: data. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- RACK VANECK ETF TR VANECK DATA CENT
GA selected RACK as a RELATED security because its canonical security name directly matches this event's themes: data. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
Price reaction, T-5 to T+3
The Phase 3 findings suggested Kodiak might have multiple threats to Regeneron’s Eylea and added more than $3 billion to the company’s market value.
Source: BioPharma Dive
The price since 28 Sep 2026: Goldman Sachs Etf Tr Data Enha (GIEQ) versus the S&P 500
Since the first closing price after “Kodiak skyrockets on positive study data for 2 eye drugs,” Goldman Sachs Etf Tr Data Enha (GIEQ) is -0.27%. The S&P 500 fund (SPY) is +0.29% over the same days, a -0.56% difference versus the market.
Who is named in “Kodiak skyrockets on positive study data for 2 eye drugs”
Companies tied to this story
- GIEQ Goldman Sachs Etf Tr Data Enha
Goldman Sachs Etf Tr Data Enha (GIEQ) is linked, with no stored direction, medium confidence in the 28 Sep 2026 story “Kodiak skyrockets on positive study data for 2 eye drugs.” Reason on file: GA selected GIEQ as a RELATED security because its canonical security name directly matches this event's themes: data. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- RACK Vaneck Etf Tr Vaneck Data Cent
In “Kodiak skyrockets on positive study data for 2 eye drugs,” Vaneck Etf Tr Vaneck Data Cent (RACK) is linked, with no stored direction, medium confidence. Reason on file: GA selected RACK as a RELATED security because its canonical security name directly matches this event's themes: data. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
How “Kodiak skyrockets on positive study data for 2 eye drugs” reaches Goldman Sachs Etf Tr Data Enha (GIEQ)
Goldman Sachs Etf Tr Data Enha (GIEQ) is the company in “Kodiak skyrockets on positive study data for 2 eye drugs,” the 28 Sep 2026 this story story.
What ties Goldman Sachs Etf Tr Data Enha (GIEQ) to the headline is this: GA selected GIEQ as a RELATED security because its canonical security name directly matches this event's themes: data. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
Also listed, Vaneck Etf Tr Vaneck Data Cent (RACK): GA selected RACK as a RELATED security because its canonical security name directly matches this event's themes: data. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
The price range for Goldman Sachs Etf Tr Data Enha (GIEQ), and the dates in the story
GIEQ traded between 41.01 and 42.36 across 6 sessions. The latest close on file is 41.10. RACK traded between 44.78 and 51.45 across 20 sessions. The latest close on file is 44.78.
A simple score for Goldman Sachs Etf Tr Data Enha (GIEQ)
21 out of 100
“Kodiak skyrockets on positive study data for 2 eye drugs” scores 21 out of 100. The score uses 1 sources, and 2 linked companies.